Table 1.
Baseline characteristics of the study population. Values are given as median (range) unless stated otherwise
| Parameter | Value |
|---|---|
| Number of patients, n | 75 |
| Caucasian, n (%) | 73 (97.3) |
| Black, n (%) | 2 (2.7) |
| Female, n (%) | 38 (50.7) |
| Age, years | 64 (19–92) |
| BSA, m2 | 1.88 (1.44–2.75) |
| Height, cm | 170 (151–198) |
| Weight, kg | 76 (49–145) |
| BMI | 26 (18–40) |
| INR | 2.5 (1.8–3.25) |
| Daily phenprocoumon dose, mg/day | 2.14 (0.75–4.50) |
| Total phenprocoumon plasma concentration, mg/l | 1.93 (0.72–5.10) |
| Nicotine habitsa | |
| User, n (%) | 9 (12.2) |
| Non-user, n (%) | 65 (87.8) |
| Alcohol consumption | |
| Patients not reporting alcohol habits | 19 (25.3) |
| 0–1 drink per week, n (%) | 22 (29.3) |
| 2–5 drinks per week, n (%) | 22 (29.3) |
| >5 drinks per week, n (%) | 12 (16.0) |
| Concomitant medication | |
| Patients with no concomitant drugs | 21 (28.0) |
| Patients using only drugs not known to interfere with phenprocoumonb | 10 (13.3) |
| Patients using potentiatingc but no attenuating drugs | 28 (37.3) |
| Patients using attenuatingd but no potentiating drugs | 2 (2.7) |
| Patients using both potentiating and attenuating drugs | 14 (18.7) |
| Indication for anticoagulation, n (%) | |
| Venous thromboembolisme | 50 (66.7) |
| Atrial fibrillatione | 11 (14.7) |
| Heart valve replacemente | 4 (5.3) |
| Other or multiple indicationse | 10 (13.3) |
BSA = body surface area; BMI = body mass index; INR = international normalised ratio
an = 74
be.g. captopril, atenolol
ce.g. amiodarone, simvastatin, L-thyroxin, allopurinol
d e.g. metformin, digitoxin, prednisolone
eTarget INR range of 2.0–3.0